Test Price
2,800 AED✅ Home Collection Available
HOXA13 Gene Hand‑Foot‑Uterus Syndrome Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين HOXA13 لمتلازمة اليد‑القدم‑الرحم في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary – Your Trusted Genetic Diagnosis Partner
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited NGS processing with deep coverage and in‑silico validation.
- Premium Logistics: Paid hospital‑grade home collection by DHA‑licensed phlebotomists, using ISO‑certified cold‑chain transport (8 AM – 11 PM).
- Clinical Guidance: Complimentary telephonic post‑test clinical interpretation session with a genetic counsellor – results explained in simple, actionable terms.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731. Most major UAE insurers accepted.
الملخص التنفيذي
اختبار الحمض النووي بتقنية التسلسل من الجيل التالي لجين HOXA13 لتشخيص متلازمة اليد والقدم والرحم بدقة تشخيصية تبلغ 99.9%. يشمل السحب المنزلي المعتمد، استشارة وراثية بعد النتيجة، ودعم التأمين المباشر. جميع الخدمات مرخصة من هيئة الصحة بدبي ومعتمدة عالميًا.
Overview – Precision Genetic Diagnosis for Reproductive Health
The HOXA13 gene hand‑foot‑uterus syndrome NGS test detects pathogenic variants linked to this rare autosomal dominant disorder, which can cause limb malformations and Müllerian duct anomalies. Using next‑generation sequencing (NGS) with full exon coverage, it provides a definitive molecular diagnosis for affected individuals and at‑risk family members.
| Feature | Our Test – HOXA13 NGS (UAE) | Closest Alternative |
|---|---|---|
| Precision | 99.9% sensitivity for SNVs/indels, validated by Sanger confirmation | Single‑gene sequencing / limited panels – may miss rare variants |
| Methodology | NGS (Next‑Generation Sequencing) with full bioinformatic annotation | Sanger sequencing (single exon at a time), slower and less comprehensive |
| Turnaround | 3–4 Weeks | Often 6–8 weeks for multi‑step approaches |
| Regulatory Compliance | DHA‑licensed, ISO 9001:2015, UAE PDPL secure | May not meet UAE genetic test law standards |
2026 ICD‑10‑CM Codes
- Q87.2 – Congenital malformation syndromes predominantly involving limbs
- Q87.8 – Other specified congenital malformation syndromes
- N97.9 – Female infertility, unspecified (when uterine anomalies present)
LOINC & Methodology
LOINC: 94076-2 – HOXA13 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method
Method: NGS (Next‑Generation Sequencing) with 100% coverage of coding exons ±10 bp splice junctions, CNV detection, and variant classification per ACMG guidelines.
DRPhysician Insight & Safety Protocol
“As a DHA‑licensed physician, I remind every patient that a genetic result is one piece of a larger clinical puzzle. The HOXA13 NGS test provides high‑resolution data, yet it must be correlated with physical examination, imaging, and family history. Never make a life‑altering decision based solely on a lab report; always discuss your results with a qualified specialist.”
— Dr. PRABHAKAR REDDY, DHA License: 61713011
Test Exclusion Criteria & Emergency Red Flags
- Not suitable for: Emergency diagnosis, prenatal aneuploidy screening (NIPT), or forensic identification.
- Pre‑requisites: A pre‑test genetic counselling session to draw a pedigree chart must be completed. Clinical history mandatory.
- Red Flags – Seek Immediate Medical Attention: If you experience acute limb pain, sudden swelling, or abnormal uterine bleeding before or after sample collection, go to the nearest emergency room. This test does not replace urgent clinical care.
- Sample rejection: Inadequate whole blood volume, incorrect anticoagulant, or FTA card with insufficient dried blood spot. Test not intended for minors without parental consent per UAE CDS Law 2026.
Frequently Asked Questions
1. What is the clinical purpose of the HOXA13 hand‑foot‑uterus syndrome NGS test?
This test confirms the molecular diagnosis of hand‑foot‑uterus syndrome by detecting disease‑causing mutations in the HOXA13 gene in individuals with suggestive limb and uterine malformations.
2. Can this be performed on a one‑drop blood sample on an FTA card?
Yes, our accredited laboratory accepts either 2‑3 mL whole blood in EDTA or a properly dried blood spot on an FTA card, providing the same high diagnostic accuracy.
3. How does UAE genetic testing law protect my data and results?
Under Federal Decree‑Law No. 41 of 2024 (Art. 87) and the UAE PDPL, all genetic data is securely encrypted, stored on UAE‑based servers, and never shared without your explicit consent.
Compliant with Federal Decree‑Law No. 41/2024 Art. 87, CDS Law 2026 (Minors), UAE PDPL
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians